Special Issue

Biomarkers in Psychiatric Disorders

Message from the Guest Editors

Biological markers—represent a promising opportunity for improving prevention, diagnosis, treatment management, as well as the development of effective therapeutic agents. While for many medical specialties, a limited number of markers are available, psychiatry still cannot rely on similar and universally shared diagnostic, prognostic, or theranostic biomarker tools. The present Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of the topic and showcase some of the latest findings in the field of Biomarkers in Psychiatric Disorders coming from genetics, transcriptomics, proteomics, metabolomics, and epigenetics. Special attention will be given to contributions directly related to the shaded area of biomarkers of treatment response pointing to the development of patient stratification strategies. Integrative approaches integrating multiple biomarkers, including molecular and phenotypic data, are welcome. Original, review, and perspective articles are highly encouraged.

Guest Editors

Prof. Dr. Massimo Clerici

Prof. Dr. Enrico Domenici

Dr. Matteo Marcatili

Deadline for manuscript submissions

closed (15 March 2023)

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).